Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

VJOncology

- PMLiVE

Longevity lessons

The secret to corporate longevity isn’t growth, it’s survival

- PMLiVE

Pfizer to supply 6 million Paxlovid treatments to low- and middle-income countries

Eligible countries will be offered treatment courses according to Pfizer’s tiered pricing approach

- PMLiVE

EC approves Alexion’s Ultomiris as generalised myasthenia gravis treatment

The positive phase 3 trial results assessing the treatment were published in NEJM Evidence

- PMLiVE

Biogen’s tofersen shows promise in rare form of ALS in new data analysis

Mutations in the SOD1 gene are responsible for approximately 2% of global ALS cases

- PMLiVE

Merck to initiate phase 3 HIV-1 clinical programme with a lower dose of islatravir

A phase 2 study evaluating islatravir with Gilead’s lenacapavir will also resume with the lower dose

- PMLiVE

Roche announces launch of HPV self-sampling solution for cervical cancer screening

Around 342,000 die from cervical cancer worldwide, despite it being a preventable disease

- PMLiVE

It’s a Medscape wrap for #EADVCongress

Medscape was on-site at this year’s EADV conference in Milan, with educational activities and a booth to connect with healthcare professionals.At our booth, we spoke with attendees about Medscape and...

Medscape Education

Leveraging the Cloud for Patient-friendly Medical Devices

Robert Kaul, Founder, CEO & President of Cloud DX, explores connected health, remote patient monitoring, telemedicine, and more. He also shares his tips for new entrepreneurs based on his 17...

Impetus Digital

- PMLiVE

The fight against antimicrobial resistance

By Jonathan Cooke

- PMLiVE

AstraZeneca’s Tezspire receives EC approval as severe asthma add-on treatment

Tezspire demonstrated superiority across every primary and key secondary endpoint compared to placebo

- PMLiVE

Merck bags NICE recommendation for renal cell carcinoma adjuvant treatment

Patients will now be able to access immunotherapy at an earlier stage in their treatment pathway

- PMLiVE

Lilly’s Retevmo approved by FDA for RET fusion+ advanced/metastatic solid tumours

Results demonstrated an overall response rate of 44% across multiple tumour types

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links